Cybin Inc. (CYBN)
AMEX AMEX Primary Summary
CYBN Chart
Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript
Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript
Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript
Cybin Inc. ( CYBN ) Q2 2026 Earnings Call November 13, 2025 8:00 AM EST Company Participants Eric So - Co-Founder, Interim CEO, President & Executive Chairman Amir Inamdar - Chief Medical Officer Greg Cavers - Chief Financial Officer George Tziras Conference Call Participants Sarah James Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Laura Suriel Eddie Hickman - Guggenheim Securities, LLC, Research Division Elemer Piros - Lucid Capital Markets, LLC, Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Eric So Co-Founder, Interim CEO, President & Executive Chairman Good morning, and thank you for joining us.
Wall Street Analysts See an 831.44% Upside in Cybin Inc. (CYBN): Can the Stock Really Move This High?
The consensus price target hints at an 831.4% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Cybin Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 148.2 | $6.97 | $0.18 | -$6.79 | -97.42% |
Cybin Inc. (CYBN) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Cybin Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric So CEO | AMEX Exchange | 23256X407 CUSIP |
| CA Country | 50 Employees | - Last Dividend | 19 Sep 2024 Last Split | - IPO Date |
Overview
Cybin Inc. is a trailblazing clinical-stage biopharmaceutical company dedicated to the development of innovative psychedelic-based therapeutics aimed at treating mental health conditions. Situated in Toronto, Canada, Cybin Inc. is at the forefront of leveraging the therapeutic potential of psychedelic compounds to address unmet needs in mental health care. With a strategic focus on research and collaborations, Cybin Inc. is advancing its diverse pipeline of psychedelic-based compounds through various stages of clinical and preclinical development, underpinned by partnerships with leading technology and healthcare organizations to enhance the delivery and efficacy of its innovative treatments.
Products and Services
- CYB003: A deuterated psilocybin analog currently undergoing a phase 1/2a clinical trial for the treatment of major depressive disorder (MDD), and in preclinical trials for alcohol use disorder. This compound represents Cybin's commitment to improving outcomes for patients suffering from MDD and potentially offering a new pathway for treating alcohol use disorder.
- CYB004: A deuterated dimethyltryptamine (DMT) that has completed a phase 2 clinical trial aimed at treating generalized anxiety disorders. CYB004 exemplifies Cybin’s exploration into treatments for anxiety, pushing the boundaries of traditional therapeutics.
- SPL028: Injectable deuterated DMT that has completed phase 1 clinical trials both intramuscularly and intravenously. This development underscores Cybin’s pursuit of alternative administration routes for psychedelic compounds to enhance patient accessibility and therapeutic efficacy.
- SPL026: Has progressed through phase 1, 1b, and 1/2a clinical trials for MDD, showcasing Cybin’s active engagement in addressing mental health disorders, particularly MDD, with novel psychedelic-based therapies.
- CYB005: A phenethylamine derivative in the preclinical stage for treating neuroinflammation. This reflects Cybin’s broader interest in exploring the potential of psychedelics beyond mental health conditions to encompass neuroinflammation, which is implicated in a variety of neurological disorders.
In support of its innovative product development, Cybin Inc. has entered into research and collaboration agreements with notable entities such as TMS Neurohealth Centers Inc., for the development of psychedelic compound-based therapeutics; Kernel, for employing Kernel flow technology to measure neural activity; and Greenbook TMS, to establish mental health centers. These partnerships illustrate Cybin's comprehensive approach to understanding and enhancing the application of psychedelics in treating mental health disorders.
